Pharmaceutical

South Korea seeks to accelerate drug reimbursement administration process

South Korea seeks to accelerate drug reimbursement admi...

Jun 22, 2024

South Korea is moving forward with reforming its national health insurance syste...

Emergent to sell US sterile manufacturing facility to Bora

Emergent to sell US sterile manufacturing facility to Bora

Jun 22, 2024

Emergent BioSolutions has agreed to divest its sterile manufacturing facility in...

Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease

Johnson & Johnson seeks FDA approval for Tremfya for Cr...

Jun 22, 2024

Johnson & Johnson (J&J) has submitted an sBLA seeking approval from the US FDA f...

TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Chol...

Jun 20, 2024

TYRA-200 is under clinical development by Tyra Biosciences and currently in Phas...

SGNB-7H4V by Pfizer for Peritoneal Cancer: Likelihood of Approval

SGNB-7H4V by Pfizer for Peritoneal Cancer: Likelihood o...

Jun 20, 2024

SGNB-7H4V is under clinical development by Pfizer and currently in Phase I for P...

SGNB-7H4V by Pfizer for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

SGNB-7H4V by Pfizer for Bile Duct Cancer (Cholangiocarc...

Jun 20, 2024

SGNB-7H4V is under clinical development by Pfizer and currently in Phase I for B...

SGNB-7H4V by Pfizer for Epithelial Ovarian Cancer: Likelihood of Approval

SGNB-7H4V by Pfizer for Epithelial Ovarian Cancer: Like...

Jun 20, 2024

SGNB-7H4V is under clinical development by Pfizer and currently in Phase I for E...

IMA-203CD8 by Immatics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

IMA-203CD8 by Immatics for Bile Duct Cancer (Cholangioc...

Jun 20, 2024

IMA-203CD8 is under clinical development by Immatics and currently in Phase II f...

SGNB-7H4V by Pfizer for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

SGNB-7H4V by Pfizer for Human Epidermal Growth Factor R...

Jun 20, 2024

SGNB-7H4V is under clinical development by Pfizer and currently in Phase I for H...

IBI-343 by Innovent Biologics for Solid Tumor: Likeliho...

Jun 20, 2024

IBI-343 is under clinical development by Innovent Biologics and currently in Pha...

ILution travoprost by Glaukos for Ocular Hypertension: Likelihood of Approval

ILution travoprost by Glaukos for Ocular Hypertension: ...

Jun 20, 2024

ILution travoprost is under clinical development by Glaukos and currently in Pha...

Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval

Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinu...

Jun 20, 2024

Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific ...

ILution travoprost by Glaukos for Open-Angle Glaucoma: Likelihood of Approval

ILution travoprost by Glaukos for Open-Angle Glaucoma: ...

Jun 20, 2024

ILution travoprost is under clinical development by Glaukos and currently in Pha...

Small Molecule to Target PSMA for Metastatic Hormone Re...

Jun 18, 2024

Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer ...

MEDI-0618 by AstraZeneca for Migraine: Likelihood of Ap...

Jun 18, 2024

MEDI-0618 is under clinical development by AstraZeneca and currently in Phase I ...

DFV-890 by Novartis for Coronary Artery Disease (CAD) (...

Jun 18, 2024

DFV-890 is under clinical development by Novartis and currently in Phase II for ...

52
53
54
55
56